REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/15/2026
Back to search
Official data from USPTO
MAGNAFOLATE-C
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
52
Latest update
08/15/2026
Trademark type
Combined
Nice classes
1, 5
Filing date
04/07/2014
Registration date
08/15/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/30/2023
Last transaction
08/15/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/01/2015
First use in commerce
02/01/2015
Drawing code
5
Owner type
99
Owner location
Jiangsu Province,, CN
Examiner
HOFFMAN, DAVID AARON
Law office
L70
Current location
TMEG LAW OFFICE 107
Mark description
The mark consists of the stylized wording "MAGNAFOLATE-C".
Holders and representatives
Holders
Lianyungang Jinkang Pharmaceutical Technology Co. Ltd
Representatives
Neal Massand Ni, Wang & Massand, PLLC
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Industrial chemicals; chemical preparations for scientific purposesother than for medical or veterinary use; calcium salts; chemical preparations and raw materials in the nature of L-5- methyl tetrahydrofolate for use in the manufacture pharmaceuticalmedical and nutritional products; chemicals for use in industry and science; chemicals for use in the pharmaceuticalnutritional and dietary industries
Class 5
Medicines for human purposesL-5- methyl tetrahydrofolate for use as a contraceptive; pharmaceutical preparations for the treatment and prevention of diseases and disorders of the respiratory systemgastrointestinal systemendocrine systemcardiovascular systemnervous systemmasculoskeletal systemurinary systemintegumentary system and reproductive system; pharmaceutical preparations for treatment of blood disease and disorder; dermatologic pharmaceutical preparations; hormone therapy preparations; pharmaceutical preparations for the treatments of coldscoughs and influenza; pharmaceutical preparations for ophthalmic use; pharmaceutical preparations for treating dandrufflaxativesanalgesicscontraceptivesantiseptics; pharmaceutical preparations for treatment of hypertension; pharmaceutical preparations for treatment of obesity; anti allergic pharmaceutical preparations; pharmaceutical preparations for treatment of gout; anti-inflammatory pharmaceuticals; contraceptive preparations; dietetic foodsfolic acid for the treatment of vitamin deficiency; dietetic substances adapted for medical usefolic acid for the treatment of vitamin deficiency; food for babies; nutritional supplements; dietary supplement for animals; antibiotics; vitamin preparations; drugs for medical purposes for the treatment of subacute encephali associated with dementia and vacuolar myelopathyphysiological and pathological vascular and cardiovascular disorders such as premature occlusive arterial diseasessevere vascular diseases in infancy and childhoodprogressive arterial stenosisintermittent claudicationrenal vascular hypertensionischemic cerebrovascular diseasespremature occlusive retinal artery and retinal veincrebral occlusive arterial diseasesocclusive peripheral arterial diseasespremature death caused by thromboembolic diseases and/or ischemic heart diseasesautoimmune diseases such as psoriasisceliac diseasearthritis and inflammatory conditionsmegaloblastic anemia caused by folate inficiencyintestinal malabsorptionused as antidote for folic acid antagonistsused for preventing serious toxic effects caused by methotrexate overdose or high-dose therapyreducing risks of woman miscarriage and/or production of fetuses with neural tube defectscleft lip and/or palate defectskeeping and/or normalizing homocysteine levels and/or metabolismchanges synthesis of and/or functions and/or variations in dna and rna and changes in synthesis of cells and depression
Publications
History of USPTO decisions and trademark events.
52 publications found
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
10/30/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
10/30/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/30/2023
ES8R
TEAS SECTION 8 RECEIVED
06/27/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/15/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/15/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/14/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/13/2017
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/06/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/05/2017
IUAF
USE AMENDMENT FILED
06/09/2017
EISU
TEAS STATEMENT OF USE RECEIVED
06/09/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/23/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/28/2017
PUBO
PUBLISHED FOR OPPOSITION
03/28/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/08/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/22/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/08/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/18/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/29/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/29/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/29/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/19/2016
GNRT
NON-FINAL ACTION E-MAILED
05/19/2016
CNRT
NON-FINAL ACTION WRITTEN
05/19/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/28/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/03/2015
GNRT
NON-FINAL ACTION E-MAILED
09/03/2015
CNRT
NON-FINAL ACTION WRITTEN
09/03/2015
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
08/14/2015
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
08/04/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/21/2015
ALIE
ASSIGNED TO LIE
07/15/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/19/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/19/2015
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/19/2015
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/05/2015
GNFR
FINAL REFUSAL E-MAILED
01/05/2015
CNFR
FINAL REFUSAL WRITTEN
01/05/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/10/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/10/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/10/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/16/2014
GNRT
NON-FINAL ACTION E-MAILED
07/16/2014
CNRT
NON-FINAL ACTION WRITTEN
07/16/2014
DOCK
ASSIGNED TO EXAMINER
07/14/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/21/2014
NWAP
NEW APPLICATION ENTERED
04/10/2014
Continuous trademark protection
Get notified about every new filing that threatens MAGNAFOLATE-C or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.